Rosacea

Latest News

DFD-29: The Journey to FDA Approval and a New Era in Rosacea Management
DFD-29: The Journey to FDA Approval and a New Era in Rosacea Management

January 9th 2025

DFD-29, FDA-approved in 2024, revolutionizes rosacea management by addressing both erythema and inflammatory lesions with a novel extended-release formulation.

Dermatology Times 2024 In Review: Rosacea
Dermatology Times 2024 In Review: Rosacea

December 23rd 2024

Patients with Rosacea are More Likely to Develop Anxiety and Depression
Patients with Rosacea are More Likely to Develop Anxiety and Depression

December 12th 2024

Advances and Challenges in Rosacea Treatment: Insights From Hilary Baldwin, MD
Advances and Challenges in Rosacea Treatment: Insights From Hilary Baldwin, MD

November 17th 2024

FDA Approves Journey Medical’s DFD-29 for Rosacea
FDA Approves Journey Medical’s DFD-29 for Rosacea

November 4th 2024

Video Interviews
Latest CME Events & Activities

21st Annual International Symposium on Melanoma and Other Cutaneous Malignancies®

February 8, 2025

View More

Expert Illustrations & Commentaries™: Picturing the Potential Role of OX40 and OX40L Inhibitors in Atopic Dermatitis

View More

Hidradenitis Suppurativa (HS): Deepening Foundations of Knowledge in Disease Pathogenesis, Disease Severity Assessment, and Treatment Decision-Making

View More

Clinical Consultations™: Optimizing Treatment Outcomes for Patients with Generalized Pustular Psoriasis

View More

Revolutionizing Atopic Dermatitis (RAD) Conference 2025

June 6-7, 2025

Register Now!

Advances in™ Atopic Dermatitis: Addressing Unmet Needs in Patients With Skin of Color

View More

Clinical Consultations™: Guiding Patients with Genital Psoriasis Toward Relief Through a Multidisciplinary Approach

View More

Patient, Provider & Caregiver Connection™: Understanding the Patient Journey to Provide Personalized Care for Generalized Pustular Psoriasis

View More

Cases and Conversations™: Applying Practice Techniques to Optimize Diagnosis and Treatment Strategies in Generalized Pustular Psoriasis

View More

Cases and Conversations™: Applying Best Practices to Prevent Shingles in Your Practice

View More

‘REEL’ Time Patient Counseling™: Fostering Effective Conversations in Practice to Create a Visible Impact for Patients Living with Genital Psoriasis

View More

Dermalorian™ Webinar: Shedding Light on Patient-Reported Outcomes to Assess Disease Severity in Patients With Atopic Dermatitis

View More

Where Do Biologics Fit Into the Management of Moderate-to-Severe Atopic Dermatitis?

View More

More News

© 2025 MJH Life Sciences

All rights reserved.